Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204644 | 0.94 | MGLL (0.47) | PLA2G7HDAC6PTGS1PTGS2MGLL | |
| SCHEMBL11264830 | 0.92 | MGLL (0.50) | PLA2G7PTGS1PTGS2MGLLFAAH | |
| SCHEMBL11252578 | 0.92 | MGLL (0.50) | PLA2G7PTGS1PTGS2MGLLFAAH | |
| SCHEMBL30372493 | 0.92 | MGLL (0.50) | PLA2G7PTGS1PTGS2MGLLFAAH | |
| SCHEMBL4447273 | 0.87 | PLA2G7 (0.50) | PLA2G7HDAC6GAAALDH1A1RECQL | |
| SCHEMBL25198948 | 0.82 | MGLL (0.38) | PTGS1PTGS2MGLLFAAHTP53 | |
| SCHEMBL9190811 | 0.82 | PLA2G7 (0.46) | PLA2G7HDAC6GAAKDM4EALDH1A1 | |
| SCHEMBL27596669 | 0.82 | HDAC6 (0.41) | HDAC6PTGS1PTGS2MGLLFAAH | |
| SCHEMBL414553 | 0.80 | F2 (0.48) | PLA2G7HDAC6MGLLGAAALDH1A1 | |
| SCHEMBL14223376 | 0.80 | SMN1; SMN2 (0.37) | PLA2G7PTGS1PTGS2MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736261-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230168582-A1 | COMPOSITION FOR FORMING RESIST UNDERLYING FILM | NISSAN CHEMICAL CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| EP-3736261-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | disclosed |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-08-10 | — | — | US | disclosed |
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-27 | — | — | US | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210697-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PLA2G7 371/4885HDAC6 485/4885PTGS1 1844/4885 |
| US-20170233332-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PLA2G7 371/4885HDAC6 485/4885PTGS1 1844/4885 |
| US-20170210698-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PLA2G7 371/4885HDAC6 485/4885PTGS1 1844/4885 |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | PLA2G7 1691/4885HDAC6 2725/4885PTGS1 3934/4885 |
| US-20170224844-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PLA2G7 371/4885HDAC6 485/4885PTGS1 1844/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | PLA2G7 1403/4885HDAC6 859/4885PTGS1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.